Equities analysts expect Danaher Co. (NYSE:DHR) to report earnings of $1.02 per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for Danaher’s earnings, with the highest EPS estimate coming in at $1.17 and the lowest estimate coming in at $0.90. Danaher reported earnings of $1.19 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The firm is scheduled to issue its next earnings results on Thursday, July 16th.
According to Zacks, analysts expect that Danaher will report full year earnings of $4.88 per share for the current year, with EPS estimates ranging from $4.60 to $5.09. For the next fiscal year, analysts anticipate that the business will post earnings of $5.72 per share, with EPS estimates ranging from $5.30 to $6.07. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Danaher.
Danaher (NYSE:DHR) last announced its earnings results on Wednesday, May 6th. The conglomerate reported $1.05 EPS for the quarter, beating the consensus estimate of $1.00 by $0.05. The company had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.32 billion. Danaher had a return on equity of 11.52% and a net margin of 16.85%. The firm’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 EPS.
Several equities research analysts recently commented on DHR shares. Citigroup lifted their price target on shares of Danaher from $180.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Zacks Investment Research upgraded shares of Danaher from a “sell” rating to a “hold” rating and set a $160.00 price objective on the stock in a research note on Wednesday, April 15th. Stifel Nicolaus lifted their target price on shares of Danaher from $147.00 to $170.00 and gave the company a “hold” rating in a report on Friday, May 8th. Credit Suisse Group upped their price target on shares of Danaher from $165.00 to $169.00 and gave the company an “outperform” rating in a report on Thursday, May 21st. Finally, Needham & Company LLC dropped their price target on shares of Danaher from $187.00 to $183.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $168.69.
In related news, SVP Daniel Raskas sold 37,082 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $164.09, for a total value of $6,084,785.38. Following the completion of the transaction, the senior vice president now directly owns 19,723 shares in the company, valued at approximately $3,236,347.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Robert S. Lutz sold 33,892 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $161.68, for a total value of $5,479,658.56. Following the completion of the transaction, the chief accounting officer now owns 18,950 shares of the company’s stock, valued at $3,063,836. The disclosure for this sale can be found here. Insiders have sold a total of 85,318 shares of company stock worth $13,941,119 over the last quarter. 11.70% of the stock is owned by company insiders.
A number of large investors have recently added to or reduced their stakes in DHR. Abbrea Capital LLC raised its stake in Danaher by 1.5% in the 1st quarter. Abbrea Capital LLC now owns 4,190 shares of the conglomerate’s stock valued at $581,000 after acquiring an additional 63 shares during the period. Laurel Wealth Advisors LLC boosted its stake in shares of Danaher by 23.7% during the 1st quarter. Laurel Wealth Advisors LLC now owns 329 shares of the conglomerate’s stock worth $46,000 after acquiring an additional 63 shares in the last quarter. Ironwood Investment Management LLC lifted its stake in Danaher by 2.1% in the 4th quarter. Ironwood Investment Management LLC now owns 3,358 shares of the conglomerate’s stock valued at $515,000 after buying an additional 69 shares in the last quarter. Farmers Trust Co. lifted its stake in Danaher by 1.1% in the 1st quarter. Farmers Trust Co. now owns 6,540 shares of the conglomerate’s stock valued at $906,000 after buying an additional 70 shares in the last quarter. Finally, Cetera Investment Advisers raised its holdings in Danaher by 4.1% in the 1st quarter. Cetera Investment Advisers now owns 1,785 shares of the conglomerate’s stock valued at $247,000 after acquiring an additional 70 shares during the last quarter. 77.80% of the stock is owned by hedge funds and other institutional investors.
Danaher stock traded down $7.37 during trading hours on Monday, hitting $165.32. 1,582,546 shares of the stock traded hands, compared to its average volume of 3,452,299. Danaher has a one year low of $119.60 and a one year high of $174.52. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.77. The firm’s 50-day moving average price is $163.30 and its two-hundred day moving average price is $153.83. The company has a market cap of $118.11 billion, a PE ratio of 37.65, a PEG ratio of 3.91 and a beta of 0.91.
The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Friday, June 26th will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.72 annualized dividend and a yield of 0.44%. Danaher’s dividend payout ratio is currently 16.29%.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments; Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.